Based on the Bioatla Inc stock forecast from 0 analysts, the average analyst target price for Bioatla Inc is not available over the next 12 months. Bioatla Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Bioatla Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Bioatla Inc’s stock price was USD 0.44. Bioatla Inc’s stock price has changed by +36.07% over the past week, +20.05% over the past month and -80.42% over the last year.
No recent analyst target price found for Bioatla Inc
No recent average analyst rating found for Bioatla Inc
Company Overview Bioatla Inc
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California. Read Less
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologi...Read More
Frequently Asked Questions About Bioatla Inc (BCAB) Stock
Stock Target Advisor's fundamental analysis for Bioatla Inc's stock is Bearish.
Unfortunately we do not have enough data on BCAB's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BCAB's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on BCAB's stock to indicate if its overvalued.
The last closing price of BCAB's stock was USD 0.44.
The most recent market capitalization for BCAB is USD 0.02B.
Unfortunately we do not have enough analyst data on BCAB's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Bioatla Inc's stock.
As per our most recent records Bioatla Inc has 65 Employees.
Bioatla Inc's registered address is 11085 Torreyana Road, San Diego, CA, United States, 92121.
You can get more information about it from Bioatla Inc's website at https://www.bioatla.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Bioatla Inc (BCAB) Stock
Stock Target Advisor's fundamental analysis for Bioatla Inc's stock is Bearish.
Unfortunately we do not have enough data on BCAB's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BCAB's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on BCAB's stock to indicate if its overvalued.
The last closing price of BCAB's stock was USD 0.44.
The most recent market capitalization for BCAB is USD 0.02B.
Unfortunately we do not have enough analyst data on BCAB's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Bioatla Inc's stock.
As per our most recent records Bioatla Inc has 65 Employees.
Bioatla Inc's registered address is 11085 Torreyana Road, San Diego, CA, United States, 92121.
You can get more information about it from Bioatla Inc's website at https://www.bioatla.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BCAB !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
